Trials / Completed
CompletedNCT04135898
A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects
A Randomized, Double-blind, Phase I Study Comparing the Pharmacokinetic and Safety of SIBP-04 and Bevacizumab in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Shanghai Institute Of Biological Products · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a randomised, double-blind, positive drug parallel controlled clinical trial in China. In the trial, it is planned to enroll 88 subjects, randomized to two treatment groups in a ratio of 1:1 to receive the test drug and the positive control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SIBP-04 | 3mg/kg, infusion in 90 minutes |
| DRUG | Bevacizumab | 3mg/kg, infusion in 90 minutes |
Timeline
- Start date
- 2019-10-23
- Primary completion
- 2020-03-16
- Completion
- 2020-03-16
- First posted
- 2019-10-23
- Last updated
- 2023-12-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04135898. Inclusion in this directory is not an endorsement.